Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04624906
Title Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM)
Acronym BRAWM
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sunnybrook Health Sciences Centre
Indications
Therapies
Age Groups: senior | adult
Covered Countries CAN


No variant requirements are available.